Last reviewed · How we verify
5 000 IU of heparin
5 000 IU of heparin is a Small molecule drug developed by Dijklander Ziekenhuis. It is currently FDA-approved.
At a glance
| Generic name | 5 000 IU of heparin |
|---|---|
| Sponsor | Dijklander Ziekenhuis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair. (PHASE4)
- Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5 000 IU of heparin CI brief — competitive landscape report
- 5 000 IU of heparin updates RSS · CI watch RSS
- Dijklander Ziekenhuis portfolio CI
Frequently asked questions about 5 000 IU of heparin
What is 5 000 IU of heparin?
5 000 IU of heparin is a Small molecule drug developed by Dijklander Ziekenhuis.
Who makes 5 000 IU of heparin?
5 000 IU of heparin is developed and marketed by Dijklander Ziekenhuis (see full Dijklander Ziekenhuis pipeline at /company/dijklander-ziekenhuis).
What development phase is 5 000 IU of heparin in?
5 000 IU of heparin is FDA-approved (marketed).
Related
- Manufacturer: Dijklander Ziekenhuis — full pipeline
- Compare: 5 000 IU of heparin vs similar drugs
- Pricing: 5 000 IU of heparin cost, discount & access